Monopar Therapeutics Inc (MNPR) has released an update.
Monopar Therapeutics Inc. has announced the green light from the Human Research Ethics Committee in Australia to begin a Phase 1 trial for its pioneering radiopharmaceutical, MNPR-101-Zr. This marks a significant milestone for the company as it moves forward with the development of this innovative treatment option.
For further insights into MNPR stock, check out TipRanks’ Stock Analysis page.
